Table 2

Baseline patient characteristicsa

Maint biotherapy (n = 33)Historical controls (n = 34)χ2
No. of patients%No. of patients%
Maximal response to biochemotherapy
 PR19581956P = 0.89
 SD14421544
Sex, male/female24/973/2722/1265/35P = 0.48
Age, <50 years/≥50 years16/1748/5224/1071/29P = 0.07
 Median (range), years48 (17–70)45 (23–65)
Southwest Oncology Group/Eastern Cooperative Oncology Group performance status, %
 01442824P = 0.10
 116491750
 239926
No. of metastatic disease (organ) sites
 1–212361029P = 0.55
 ≥321642471
Sites of metastases
 Lung± soft tissue/lymph node only721926P = 0.61
 All other visceral26792574
Elevated lactate dehydrogenase
 (>190 IU/liter)1650b1647P = 0.81
Prior treatment
 IFN824618P = 0.90
 Chemotherapy26824P = 0.05
Time, stage IV diagnosis to biochemotherapy
 start, median (range), months2.2 (0–45)2.5 (0–35)P = 0.91
  • a All except “Maximal response to biochemotherapy” evaluated before start of biochemotherapy.

  • b n = 32; data unavailable.